[Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine].
A 6-week double-blind, parallel group study compared paroxetine and fluoxetine in 106 depressed geriatric inpatients (aged 65 to 85 years). Patients presenting acutely with major depressive episode DSM-III-R 296.2 (HAMD > 18 on 21 item scale) were randomized to receive paroxetine (20-40 mg, n = 54) or fluoxetine (20-60 mg, n = 52) following a 3-7 day washout. Primary criteria was the reduction of Hamilton Depression Rating Scale Score (HAMD). Furthermore Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression Scale (CGI) were used. Cognitive functions were assessed with the Mini-Mental-State Examination (MMSE) and the Sandoz Clinical Assessment Geriatric Scale (SCAG). The results showed a comparable reduction in the depression rating scales between the two treatment groups after 6 weeks. However, there was a statistically significant difference (p < 0.05) in HAMD, MADRS, SCAG, MMSE and cognitive subscales of HAMD and SCAG at week 3 in favour of paroxetine, which even was seen after 6 weeks in the SCAG. There were no significant differences between the treatment groups and the number of adverse events reported or in overall tolerability.
Bezirkskrankenhaus für Neurologie u. Psychiatrie, Arnsdorf bei Dresden.
W
W
Schöne
M
M
Ludwig
D000368:Aged; D000369:Aged, 80 and over; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D005473:Fluoxetine; D017374:Paroxetine
Paroxetin in der Depressionsbehandlung geriatrischer Patienten--eine doppelblinde Vergleichsstudie mit Fluoxetin.